Seattle Genetics, Inc. and Genmab A/S have entered into an additional antibody-drug conjugate (ADC) collaboration. Under the new agreement, Genmab will pay an upfront fee of $11 million for exclusive ...

COPENHAGEN, Sept 14 (Reuters) - Danish biotech company Genmab A/S will collaborate in cancer drug research with Seattle Genetics under a strategy to focus on strategic partnerships for drug ...

A pivotal trial of Seattle Genetics' experimental cancer-targeting antibody for patients with Hodgkin's lymphoma found that more than a third of them achieved complete remission of their cancer. The ...

-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...

LOS ANGELES, Sept 24 (Reuters) - Biotechnology company Seattle Genetics will announce on Monday results from a pivotal trial of experimental drug brentuximab vedotin in patients with Hodgkin lymphoma.

Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago. These figures are ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Seattle Genetics (SGEN) reports results for the quarter ended September 2023. While this widely-known consensus ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Drug development partner Takeda is paying Seattle Genetics ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. One of the largest biotechs in the Puget Sound region will ...